论文部分内容阅读
我们用心得安和立其丁治疗流行性出血热(EHF)少尿期急性肾功能衰竭(ARF)25例,取得一定疗效,现报道如下。临床资料病例选自于1987年1月～1992年10月住院治疗患者,各例诊断均符合卫生部卫生防字[87]4号文颁发的标准,部份病例经检测 EHF 抗体所证实。病例随机分治疗组与对照组,两组各25例,治疗前两组基础情况(包括性别、年龄、职业、低血压休克期血压变化与输液成份及数量、已少尿病日、血BUN 及 Cr 值,血压等)无显著性差异。治疗方法:治疗组,心得安10～20mg、一日三次,立其丁每日0.6mg/kg 加500ml 液体中滴入、每分钟10滴左右,进入多尿期后停用二药;对照组,用速尿或利尿合剂等。一般治疗两组相同。两组病例均逐日记尿量及查尿蛋白,每1～2天查一次 BUN 及 Cr。结果,治疗组疗效显著优于对照组,少尿期平均缩短2.08天(P<0.01),尿蛋白消失提前2.42天(P<0.01),肾功能提前2.23天(P<0.01)恢复正常。讨论ARF 是 EHF 最常见而严重的临床表现及主要死亡原因。EHF 少尿除与病毒的直接损害,免疫损伤和 DIC 外,与血浆血管紧张素Ⅱ(AT-Ⅱ)和儿
We used propranolol and Lidin treatment of epidemic hemorrhagic fever (EHF) oliguric acute renal failure (ARF) in 25 cases, and achieved a certain effect, are reported below. Cases of clinical data were selected from hospitalized patients from January 1987 to October 1992. The diagnosis of each case was in line with the standard issued by the Ministry of Health on the prevention of anti-word [87] No. 4, and some cases were confirmed by the detection of EHF antibody. The cases were randomly divided into treatment group and control group, with 25 cases in each group. The basic conditions (including gender, age, occupation, blood pressure changes and infusion composition and quantity in the shock stage, oligohydration day, blood BUN, Cr value, blood pressure, etc.) no significant difference. Treatment: The treatment group, propranolol 10 ~ 20mg, three times a day, the daily Ding Li Ding 0.6mg / kg plus 500ml liquid drip, about 10 drops per minute, into the polyuria after the withdrawal of two drugs; control group , With furosemide or diuretic mixture. The same general treatment of two groups. Two groups of patients were diary daily diuresis and check urinary protein, check every 1 to 2 days BUN and Cr. The results showed that the treatment group was significantly better than the control group. The oliguria period was 2.08 days on average (P <0.01). Discussion ARF is the most common and severe EHF clinical manifestations and the main cause of death. EHF oliguria in addition to direct damage with the virus, immune injury and DIC, and plasma angiotensin Ⅱ (AT-Ⅱ) and children